116 related articles for article (PubMed ID: 16600177)
1. CRIT peptide interacts with factor B and interferes with alternative pathway activation.
Hui KM; Magnadóttir B; Schifferli JA; Inal JM
Biochem Biophys Res Commun; 2006 May; 344(1):308-14. PubMed ID: 16600177
[TBL] [Abstract][Full Text] [Related]
2. Expression of functional recombinant von Willebrand factor-A domain from human complement C2: a potential binding site for C4 and CRIT.
Hui KM; Orriss GL; Schirmer T; Magnadóttir B; Schifferli JA; Inal JM
Biochem J; 2005 Aug; 389(Pt 3):863-8. PubMed ID: 15823096
[TBL] [Abstract][Full Text] [Related]
3. Identification of Complin, a novel complement inhibitor that targets complement proteins factor B and C2.
Kadam AP; Sahu A
J Immunol; 2010 Jun; 184(12):7116-24. PubMed ID: 20483772
[TBL] [Abstract][Full Text] [Related]
4. Complement C2 receptor inhibitor trispanning and the beta-chain of C4 share a binding site for complement C2.
Inal JM; Schifferli JA
J Immunol; 2002 May; 168(10):5213-21. PubMed ID: 11994478
[TBL] [Abstract][Full Text] [Related]
5. Role of early lectin pathway activation in the complement-mediated killing of Trypanosoma cruzi.
Cestari Idos S; Krarup A; Sim RB; Inal JM; Ramirez MI
Mol Immunol; 2009 Dec; 47(2-3):426-37. PubMed ID: 19783051
[TBL] [Abstract][Full Text] [Related]
6. A peptide derived from the parasite receptor, complement C2 receptor inhibitor trispanning, suppresses immune complex-mediated inflammation in mice.
Inal JM; Schneider B; Armanini M; Schifferli JA
J Immunol; 2003 Apr; 170(8):4310-7. PubMed ID: 12682267
[TBL] [Abstract][Full Text] [Related]
7. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
[TBL] [Abstract][Full Text] [Related]
8. Oxiagin from the Naja oxiana cobra venom is the first reprolysin inhibiting the classical pathway of complement.
Shoibonov BB; Osipov AV; Kryukova EV; Zinchenko AA; Lakhtin VM; Tsetlin VI; Utkin YN
Mol Immunol; 2005 Jun; 42(10):1141-53. PubMed ID: 15829304
[TBL] [Abstract][Full Text] [Related]
9. A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models.
Subías M; Tortajada A; Gastoldi S; Galbusera M; López-Perrote A; Lopez Lde J; González-Fernández FA; Villegas-Martínez A; Dominguez M; Llorca O; Noris M; Morgan BP; Rodríguez de Córdoba S
J Immunol; 2014 Dec; 193(11):5567-75. PubMed ID: 25355917
[TBL] [Abstract][Full Text] [Related]
10. Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b.
DiLillo DJ; Pawluczkowycz AW; Peng W; Kennedy AD; Beum PV; Lindorfer MA; Taylor RP
Mol Immunol; 2006 Mar; 43(7):1010-9. PubMed ID: 15961157
[TBL] [Abstract][Full Text] [Related]
11. Contribution of the complement control protein modules of C2 in C4b binding assessed by analysis of C2/factor B chimeras.
Xu Y; Volanakis JE
J Immunol; 1997 Jun; 158(12):5958-65. PubMed ID: 9190950
[TBL] [Abstract][Full Text] [Related]
12. 3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase.
Torreira E; Tortajada A; Montes T; Rodríguez de Córdoba S; Llorca O
Proc Natl Acad Sci U S A; 2009 Jan; 106(3):882-7. PubMed ID: 19136636
[TBL] [Abstract][Full Text] [Related]
13. A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors.
Paixão-Cavalcante D; Torreira E; Lindorfer MA; Rodriguez de Cordoba S; Morgan BP; Taylor RP; Llorca O; Harris CL
J Immunol; 2014 May; 192(10):4844-51. PubMed ID: 24729617
[TBL] [Abstract][Full Text] [Related]
14. Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay.
Harris CL; Pettigrew DM; Lea SM; Morgan BP
J Immunol; 2007 Jan; 178(1):352-9. PubMed ID: 17182573
[TBL] [Abstract][Full Text] [Related]
15. The complement inhibitor, CRIT, undergoes clathrin-dependent endocytosis.
Inal J; Miot S; Schifferli JA
Exp Cell Res; 2005 Oct; 310(1):54-65. PubMed ID: 16112669
[TBL] [Abstract][Full Text] [Related]
16. Screening biomaterials for functional complement activation in serum.
Lyle DB; Bushar GS; Langone JJ
J Biomed Mater Res A; 2010 Jan; 92(1):205-13. PubMed ID: 19172622
[TBL] [Abstract][Full Text] [Related]
17. Mutations of the type A domain of complement factor B that promote high-affinity C3b-binding.
Hourcade DE; Mitchell LM; Oglesby TJ
J Immunol; 1999 Mar; 162(5):2906-11. PubMed ID: 10072540
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the initial C3 convertase of the alternative pathway of human complement.
Fishelson Z; Pangburn MK; Müller-Eberhard HJ
J Immunol; 1984 Mar; 132(3):1430-4. PubMed ID: 6559201
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of the A domain from complement factor B reveals an integrin-like open conformation.
Bhattacharya AA; Lupher ML; Staunton DE; Liddington RC
Structure; 2004 Mar; 12(3):371-8. PubMed ID: 15016353
[TBL] [Abstract][Full Text] [Related]
20. Coexistence of closed and open conformations of complement factor B in the alternative pathway C3bB(Mg2+) proconvertase.
Torreira E; Tortajada A; Montes T; Rodríguez de Córdoba S; Llorca O
J Immunol; 2009 Dec; 183(11):7347-51. PubMed ID: 19890040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
